Firsocostat + Fenofibrate
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH)
Conditions
Nonalcoholic Steatohepatitis (NASH)
Trial Timeline
Sep 23, 2016 → May 13, 2019
NCT ID
NCT02891408About Firsocostat + Fenofibrate
Firsocostat + Fenofibrate is a phase 1 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02891408. Target conditions include Nonalcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02891408 | Phase 1 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH)